Mersana Therapeutics (MRSN) Short-Term Debt to Equity

Graphic logo of Mersana Therapeutics (MRSN)

The market capitalization trend for Mersana Therapeutics (MRSN) on the GURU.Markets platform is 0.00. Mersana Therapeutics (MRSN) generates revenue through the development of ADC drugs and strategic alliances with industry leaders. Meanwhile, the risk of disrupted logistics chains and challenges with international software patenting create a certain vulnerability. However, the humanitarian status of its developments in female oncology ensures the stability of US trials regardless of trade wars.

MRSN - Mersana Therapeutics Short-Term Debt to Equity Ratio over the range 07/04/2022 - 01/17/2026

Financial and market metric breakdowns for Mersana (MRSN)

- stock quotes and analyst forecast:
Stock Price Mersana Therapeutics|MRSN - Analyst Consensus Forecast
- market capitalization details:
Market Value Mersana Therapeutics Inc|MRSN - Business Value
- balance sheet equity data:
Book Value per Share Mersana Therapeutics|MRSN - Company Net Assets|Market Capitalization to Book Value Ratio mersana.com|MRSN - Company Assets
- business debt structure and liquidity details:
Debt to Equity Mersana Therapeutics|MRSN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Mersana Therapeutics|MRSN - Aggregate Debt Obligations|Debt to Book Value Mersana Therapeutics Inc|MRSN - Company Long-Term Liabilities|Company Short-Term Debt Mersana Therapeutics|Quick Liquidity mersana.com
- earnings and market ratios statistics:
MRSN - Net Income
Fundamental valuation:Mersana Therapeutics, Inc. MRSN
Signature product of mersana.com

This ratio measures the proportion of short-term liabilities relative to shareholders' equity, determining the liquidity and default risk of the company over the next twelve months. By analyzing the short-term debt to equity ratio, an investor assesses the financial stability of Mersana Therapeutics (MRSN) while scaling the Dolaflexin platform and developing innovative ADC drugs for ovarian cancer therapy.

Competitors of Mersana Therapeutics

Short-Term Debt to Capital MRUS|Short-Term Debt to Capital Immutep Corp (IMMP)|Short-Term Debt to Equity Anixa Biosciences, Inc. ANIX|ATOS: Short-Term Debt to Capital Ratio|Context Tx - Short-Term Debt to Capital|BriaCell Therapeutics Corp. (BCTX) - Short-Term Debt to Equity Ratio|EPIX: Short-Term Debt to Capital|Current Liabilities to Capital QT Imaging, Inc. (QTI)